Insider Transactions in Q1 2022 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2022
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
161,139
-41.9%
|
$2,739,363
$17.26 P/Share
|
|
Mar 10
2022
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
148,302
+42.69%
|
$444,906
$3.22 P/Share
|
|
Mar 07
2022
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
20,000
-8.0%
|
$340,000
$17.16 P/Share
|
|
Mar 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
2,300
-17.04%
|
$39,100
$17.2 P/Share
|
|
Mar 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+14.56%
|
$9,200
$4.73 P/Share
|
|
Feb 28
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
301
+0.9%
|
$4,816
$16.61 P/Share
|
|
Feb 28
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
602
+3.58%
|
$9,632
$16.61 P/Share
|
|
Feb 28
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,128
+1.39%
|
$18,048
$16.61 P/Share
|
|
Feb 28
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
602
+22.62%
|
$9,632
$16.61 P/Share
|
|
Feb 15
2022
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$90,000
$18.5 P/Share
|
|
Feb 15
2022
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Jan 11
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
184,000
-16.95%
|
$2,760,000
$15.04 P/Share
|
|
Jan 11
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
184,000
+14.49%
|
$736,000
$4.73 P/Share
|